Yayınlar & Eserler

Yayın Ağı
Makaleler 32
Tümü (32)
SCI-E, SSCI, AHCI (26)
SCI-E, SSCI, AHCI, ESCI (30)
ESCI (4)
Scopus (31)
TRDizin (3)

1. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

SÜTCÜOĞLU O., AKDOĞAN O., Onur İ. D., Çiftçi A., Alkan A., Majidova N., et al.
Discover Oncology , cilt.17, sa.1, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

2. Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)

Akkus E., Kayaalp M., Ergözoğlu M. A., Koç Kuş I., Bayram D., Kılıçtaş B., et al.
JCO global oncology , cilt.12, sa.3, 2026 (ESCI, Scopus) identifier identifier identifier

3. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

KÖKSAL B., Yildirim H. C., GÜVEN D. C., Kose F., Koymen G., Ozdemir O., et al.
Journal of Clinical Medicine , cilt.15, sa.4, 2026 (SCI-Expanded, Scopus) identifier identifier

4. Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases

AKDOĞAN O., Canaslan K., Hamitoglu B., YAZICI O., SÜTCÜOĞLU O.
Journal of Clinical Oncology , 2026 (SCI-Expanded, Scopus) identifier identifier identifier

5. Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer

AKDOĞAN O., BÖLEK H., Baskurt K., Akay Hacan B., SÜTCÜOĞLU O., Bir Yucel K., et al.
CANCER INVESTIGATION , cilt.44, sa.3, ss.248-256, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

6. Key Methodological Considerations in the Interpretation of the CONKO-007 Trial

AKDOĞAN O., ÖZET A., YAZICI O., ÖZDEMİR N., SÜTCÜOĞLU O.
Journal of Clinical Oncology , 2026 (SCI-Expanded, Scopus) identifier identifier identifier

7. Evaluation of 30-day mortality rate following intravenous systemic anticancer therapy: a retrospective analysis

ÇETİN T. E., SÜTCÜOĞLU O., AKDOĞAN O., SAVAŞ G., Günel N., ÜNER A., et al.
BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

8. Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study

Efil S. C., Bilgin B., Bilgetekin I., Helvaci K., Sakalar T., Nayir E., et al.
Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

9. Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study)

Onur İ. D., Özdemir P. A., AKDOĞAN O., Başkurt K., Kara M. I., Kalkan D. Ö., et al.
SUPPORTIVE CARE IN CANCER , cilt.33, sa.12, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

10. Evaluating the role of step counts in predicting readmission and mortality (STEP-CANCER)

SÜTCÜOĞLU O., AKDOĞAN O., Uyar G. C., ÖZET A., Baskurt K., Ozdemir N., et al.
ANNALS OF ONCOLOGY , cilt.36, 2025 (SCI-Expanded, Scopus) identifier

11. Biological age predicts survival outcomes in patients treated with immune checkpoint inhibitor monotherapy: A retrospective analysis

Tuzcu T. U., SÜTCÜOĞLU O., AKDOĞAN O., YAZICI O., ÖZDEMİR N., ÖZET A.
ANNALS OF ONCOLOGY , cilt.36, 2025 (SCI-Expanded, Scopus) identifier

12. Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey

AKDOĞAN O.
Journal of Cancer Policy , cilt.45, 2025 (ESCI, Scopus) identifier identifier identifier

13. Immunomodulatory effect of cisplatin versus carboplatin on tumor microenvironment and anti-PD-1 response: A multicenter real-world analysis

AKDOĞAN O., BÖLEK H., Baskurt K., Hacan B. A., SÜTCÜOĞLU O., Yucel K. B., et al.
ANNALS OF ONCOLOGY , cilt.36, 2025 (SCI-Expanded, Scopus) identifier

14. Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX

UgurTuzcu T., SÜTCÜOĞLU O., AKDOĞAN O., YAZICI O., ÖZDEMİR N.
LANCET ONCOLOGY , cilt.26, sa.8, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier identifier

15. Rezeksiyon Edilmiş Uterin Karsinosarkom Tanılı Hastalarda Prognostik Bir Gösterge Olarak Tanı Anındaki Menopozal Durum

Bolek H., Yalçıner M., sekmek s., CEYLAN F., akdogan o., UNCU D., et al.
Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.78, sa.2, ss.120-127, 2025 (TRDizin) identifier

16. Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey

AKDOĞAN O., SÜTCÜOĞLU O., Yucel K. B., YAZICI O., ÖZET A., ÖZDEMİR N.
JOURNAL OF CANCER POLICY , cilt.44, 2025 (ESCI, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

17. Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization

Hacioglu M. B., Kucukarda A., Gokmen I., Gurbuz A. F., Araz M., Kahvecioglu F. A., et al.
Prostate , cilt.85, sa.7, ss.693-702, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

18. Effect of a ChatGPT-based digital counseling intervention on anxiety and depression in patients with cancer: A prospective, randomized trial

AKDOĞAN O., Uyar G. C., Yesilbas E., Baskurt K., MALKOÇ N. A., ÖZDEMİR N., et al.
EUROPEAN JOURNAL OF CANCER , cilt.221, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

19. The role of enteral nutrition in cancer patients - methodological adjustments and recommendations

Uyar G. C., AKDOĞAN O., SÜTCÜOĞLU O.
SUPPORTIVE CARE IN CANCER , cilt.33, sa.3, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

20. Assessment of the CALLY Index, a Novel Immunonutrivite Marker, in Perioperatively Treated Gastric Cancer Patients Perioperatif Tedavi Görmüş Mide Kanseri Hastalarında Yeni Bir İmmünonutrisyonel Belirteç Olarak CALLY İndeksi Değerlendirilmesi

AKDOĞAN O., Yücel K. B., YAZICI O., ÖZET A., ÖZDEMİR N.
Gazi Medical Journal , cilt.36, sa.1, ss.85-90, 2025 (ESCI, Scopus, TRDizin) identifier identifier identifier

21. Impact of Serum GDF-15 and IL-6 on Immunotherapy Response in Cancer: A Prospective Study

AKDOĞAN O., TÜRKMEN S., Uyar G. C., Yucel K. B., TÜFEKÇİ B., GÜRLER F., et al.
CANCERS , cilt.16, sa.24, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

22. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center

Barlas T., Sutcuoglu O., Akdogan O., Balos Toruner F. S., Akturk M. Y., Özdemir N., et al.
ENDOCRINE-RELATED CANCER , cilt.31, sa.11, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

23. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study

Şenocak Taşçı E., Mutlu A. U., Saylık O., ÖLMEZ Ö. F., BİLİCİ A., Sünger E., et al.
CANCERS , cilt.16, sa.18, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

24. The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer

Akdogan O., Ogut B., Sutcuoglu O., Sert A., Gurler F., Akyurek N., et al.
BMC CANCER , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

25. Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms

Gürler F., Aktürk Esen S., Kurt İnci B., Sütçüoğlu O., Uçar G., Akdoğan O., et al.
CANCER INVESTIGATION , cilt.42, sa.2, ss.141-154, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

26. Correspondence: Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

AKDOĞAN O., SÜTCÜOĞLU O., ÖZET A., YAZICI O., ÖZDEMİR N.
Supportive Care in Cancer , cilt.31, sa.8, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

27. The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective

SÜTCÜOĞLU O., ERDAL Z. S., Akdoğan O., ÇELTİKÇİ E., ÖZDEMİR N., ÖZET A., et al.
Turkish Journal of Medical Sciences , cilt.53, sa.1, ss.420-431, 2023 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier identifier

28. Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer

AKDOĞAN O., Sutcuoglu O., Ogut B., Akyurek N., Ozdemir N., Ozet A., et al.
IMMUNOTHERAPY , cilt.14, sa.14, ss.1121-1131, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

29. Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists

Suticen E., Atas N., AVANOĞLU GÜLER A., AKDOĞAN O., Babaoglu H., SATIŞ H., et al.
CLINICAL RHEUMATOLOGY , cilt.40, sa.7, ss.2865-2871, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

30. The role of serum albumin/globulin ratio in combination with prognostic risk indexes of febrile neutropenia

Sütcüoğlu O., Akdoğan O., Gürler F., Kurt İnci B., Özdemir N., Özet A., et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , cilt.75, sa.7, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

31. Comment on: Inpatient epidemiology and economic burden of granulomatosis with polyangiitis: a 10-year study of the national inpatient sample

Satis H., Kayahan N., Babaoglu H., Akdogan O., YAPAR D.
RHEUMATOLOGY , cilt.59, sa.12, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

32. Comparison of definitive chemoradiotherapy and surgical results in local advanced (stage iiia and iiib) non-small cell lung cancer: single-center experience

YILMAZ M., YÜCEL B., KİRMAN D., AKDOĞAN O., YAZICI O.
Cumhuriyet Medical Journal , 2019 (Scopus) Sürdürülebilir Kalkınma
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 4

1. Prospective observational study to assess the prophylactic effect of topical diclofenac in preventing the development of hand foot syndrome in patients with colorectal and gastric cancer on capecitabine therapy

Yazıcı O., Akdoğan O., Eryildiz Yucel S., Bir Yücel K., Gürler F., Özet A., et al.
ESMO CONGRESS 2024 , Barcelona, İspanya, 13 - 17 Eylül 2024, ss.13, (Özet Bildiri) Creative Commons License

2. Assessing Mortality Rates Within 30 Days Following the Last Dose of Immunotherapy A MultiCenter Retrospective Study

BAŞKURT K., AKDOĞAN O., KARATEKE Y. S., DELİKTAŞ ONUR İ., YAZICI O., YILDIZ B., et al.
ESMO CONGRESS 2024, Barcelona, İspanya, 13 - 17 Eylül 2024, (Özet Bildiri)

3. İmmün kontrol noktası inhibitörlerine bağlı endokrinolojik yan etkiler ile kemokin ve sitokin düzeylerinin öngördürücü rolü: Prospektif çalışma

Barlas T., Sütcüoğlu O., Akdoğan O., Törüner F. S., Aktürk M. Y., Özdemir N., et al.
45. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, Antalya, Türkiye, 17 - 20 Ekim 2024, ss.100, (Tam Metin Bildiri) Creative Commons License

4. NÖTROPENİK ATEŞ İLEBAŞVURAN HASTADAGÜNCEL RİSK İNDEKSLERİYETERLİ Mİ?

SÜTCÜOĞLU O., AKDOĞAN O., GÜRLER F., KURT İNCİ B., ÖZDEMİR N., YAZICI O.
TTOD Sanal Kongresi, Türkiye, 12 - 15 Kasım 2020, (Özet Bildiri)
Metrikler

Yayın

38

Yayın (WoS)

30

Yayın (Scopus)

31

Atıf (WoS)

62

H-İndeks (WoS)

5

Atıf (Scopus)

65

H-İndeks (Scopus)

5

Atıf (Scholar)

7

H-İndeks (Scholar)

2

Atıf (TrDizin)

1

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

1

Proje

3
BM Sürdürülebilir Kalkınma Amaçları